Abstract: Disclosed herein are methods of treating addiction to a dopamine-producing agent (e.g., amphetamine, cocaine, nicotine, opioids) in patient populations that do not exclude alcohol consumption during treatment.

Abstract: Disclosed is a novel combination therapy to reduce or prevent the acquisition of a conditioned response in a mammal comprising administering to the mammal a therapeutically effective amount of an aldehyde dehydrogenase (ALDH-2) inhibitor compound, such as a compound of Formula (I), in combination with a substance that produces the conditioned response, such as a medication containing a dopamine-producing agent such as an opioid, whereby the combination acts to reduce or prevent the acquisition of a conditioned response, and the deleterious side-effect of misuse, dependence, abuse, and/or addiction.

Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

Abstract: A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.

Abstract: This invention relates to the identification of restriction fragment length polymorphisms (RFLP) of the human pancreatic cholesterol esterase gene. Specifically, the invention relates to the use of RFLP analysis for identifying individuals with a particular genetic variant of the human pancreatic cholesterol esterase gene. The invention also relates to treatment of individuals with therapeutic drugs for the prevention or alleviation of disease states in a human related to cholesterol metabolism.

Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.

Abstract: This invention encompasses methods for inhibiting and/or treating gastric and duodenal ulcers by the administration of purified, high molecular weight sulfated polysaccharide compositions.

Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.

Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quantities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme. A method for recovering a solution of purified human pancreatic cholesterol esterase having a molecular weight of about 100,000 daltons is disclosed. The 100,000 dalton fraction of human pancreatic cholesterol esterase is purified first, by preparing a solution of dialyzed human pancreatic cytosol containing the esterase and other proteins. Next, the solution is passed over a hydroxyapetite column and then eluted to yield all of the molecular weight fractions of the esterase and other proteins in the solution present as a single peak to give a first eluent.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: This invention is a method for measuring the ability of a human to absorb cholesterol. The method uses two different cholesterol tracers, the first injected into the blood stream and the second ingested by the human subject. After a waiting period a blood sample is taken from the human subject and analyzed to determine percent cholesterol absorption based on the actual amounts of the two naturally occurring, metabolically stable cholesterol tracers in the blood. The method of this invention is useful in identifying human subjects as high cholesterol absorbers and thereafter administering therapeutic agents to the subject that inhibit the absorption of cholesterol.

Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme.

Abstract: A method for recovering a purified 52,000 dalton fraction of human pancreatic cholesterol esterase is disclosed. The 52,000 dalton fraction of human pancreatic cholesterol esterase is purified by passing a solution having a pH of about 8.2 which contains two or more fractions of human pancreatic cholesterol esterase including the 52,000 dalton fraction over DEAE-cellulose to produce an effluent containing said 52,000 dalton fraction. Since the 52,000 dalton fraction of the esterase does not bind to the DEAE-cellulose whereas the other esterase fractions do bind to the DEAE-cellulose, the 52,000 dalton fraction is then collected in the effluent. The method can be further carried out by passing the purified 52,000 dalton fraction over both hydroxyapatite and heparin-Sepharose to obtain a homogeneous solution of the 52,000 dalton fraction.

Abstract: The invention provides methods for the purification to homogeneity of pancreatic cholesterol esterase in useful quanities from a variety of mammalian species. The gene for a mammalian pancreatic cholesterol esterase has been cloned and sequenced, and is useful for expressing cholesterol esterase in a transformed eukaryotic or prokaryotic cell culture. Thus, methods according to the invention enable the production of large quantities of pancreatic cholesterol esterase for the screening of inhibitors, the production of antibodies, and for commercial purposes related to the alteration of cholesterol/cholesterol ester composition of materials containing free or esterified cholesterol.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: This invention encompasses a method and compositions which inhibit pancreatic cholesterol esterase and triglyceride lipase and hence, lower cholesterol and triglycerides in the blood stream.

Abstract: An affinity resin containing pyrazole immobilized on a solid insoluble support by a coupling arm bonded at the 4-position having a length of at least 12 Angstrom units is used to purify and fractionate crude alcohol dehydrogenase extract into a pyrazole-binding fraction and a pyrazole-insensitive fraction containing the anodic band by bringing the resin into contact with an aqueous solution of a binary complex of alcohol dehydrogenase and NAD to bind the binary complex, then eluting the complex. The bound fraction can be further fractionated into isoenzymes during elution by adjusting the alcohol gradient of the eluant, and the anodic band can be separated from the remainder of the solution, which does not bind to pyrazole, by salting out and chromatography on agarose-AMP resin.